重写血管脚本:表观遗传修饰剂作为肺高血压中代谢重编程的脚本
Runxiu Zheng1,2, Junlan Tan3,2, Xianya Cao1,2
1School of Integrated Chinses and Western Medicine, Hunan University of Chinese Medicine, Changsha, 410208, Hunan, China.
肺高血压 (PH) 涉及由代谢问题和表观遗传改变驱动的血管细胞变化. 针对这些可逆的表观遗传变化为开发有效的PH治疗提供了有希望的新途径.
科学领域:
- 心血管研究
- 代谢疾病
- 表观遗传学
背景情况:
- 肺高血压 (PH) 是一种严重的心血管疾病,其特征是肺血管重塑.
- 目前治疗PH的有效性有限,需要新的治疗策略.
- 了解PH的基本分子机制对于提高患者护理至关重要.
研究的目的:
- 研究血管细胞功能障碍和代谢重编程在PH中的作用.
- 探索表观遗传修饰和细胞代谢在PH发病过程中的相互作用.
- 通过检查可逆表观遗传变化来确定潜在的治疗点.
主要方法:
- 关于PH,表观遗传学和细胞代谢的现有科学文献的审查.
- 分析表观遗传异常如何影响血管细胞中的代谢酶表达.
- 在PH期间血管细胞中的代谢变化 (葡萄糖,脂质,氨基酸) 的解脱.
主要成果:
- 表观遗传异常被确定为PH代谢失调的关键驱动因素.
- 血管细胞内的葡萄糖,脂质和氨基酸代谢的特定变化得到了突出说明.
- 可逆表观遗传变化被提出为治疗干预的潜在目标.
结论:
- 表观遗传修饰和代谢重编程是PH病理的核心.
- 针对这些可逆表观遗传变化为新型PH疗法提供了有前途的策略.
- 对表观遗传和代谢途径的进一步研究可以加速PH的有效治疗方法的开发.
更多相关视频
07:11Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Epigenetic Regulation
X-chromosome...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Chromatin Modification in iPS Cells
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
